Ambey Laboratories Limited — Others, 13-11-2024: Statement of deviation(s) or variation(s) under Reg. 32

The Board of AMBEY LABORATORIES LIMITED has approved the Compliance with the Statement of Deviation in fund utilization for the half-year ended September 30, 2024, confirming that there has been no deviation from the original objectives in the use of funds raised through its Initial Public Offering (IPO), amounting to ₹42.55 crore. Additionally, the Board noted the Certificate of Non-Applicability regarding the Disclosure of Related Party Transactions, affirming that such disclosures are not required due to the Company’s listing status on the SME Exchange. This clarity on fund usage and governance may support a positive outlook for investors.